B2M and neoplasm: Mutations in ATLL that help tumor cells avoid immune surveillance include mutations in B2M, HLA-A, HLA-B, CD58, FAS, and PD-1, as well as those interfering with TRAIL-mediated apoptosis and IAP expression [17].